Latest Sirolimus Stories
Researchers have discovered how a protein "master regulator" goes awry, leading to metastasis, the fatal step of cancer.
In an international Phase III randomized study, everolimus, when combined with the hormonal therapy exemestane, has been shown to dramatically improve progression-free survival.
Combination treatment with everolimus, an inhibitor of the mammalian target rapamycin (mTOR), and octreotide has shown to improve progression-free survival for patients with advanced neuroendocrine tumors and a history of carcinoid syndrome.
- An armed gangster.